Frank G Schaap

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3160321/publications.pdf

Version: 2024-02-01

109 papers	6,248 citations	81900 39 h-index	71685 76 g-index
109 all docs	109 docs citations	109 times ranked	8888 citing authors

#	Article	IF	Citations
1	Postprandial rise of essential amino acids is impaired during critical illness and unrelated to smallâ€intestinal function. Journal of Parenteral and Enteral Nutrition, 2022, 46, 114-122.	2.6	7
2	Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2022, 322, E132-E140.	3.5	10
3	New Kids on the Block: Bile Salt Conjugates of Microbial Origin. Metabolites, 2022, 12, 176.	2.9	7
4	Ring Trial on Quantitative Assessment of Bile Acids Reveals a Method- and Analyte-Specific Accuracy and Reproducibility. Metabolites, 2022, 12, 583.	2.9	5
5	Parenteral nutrition impairs plasma bile acid and gut hormone responses to mixed meal testing in lean healthy men. Clinical Nutrition, 2021, 40, 1013-1021.	5.0	9
6	Unaltered Liver Regeneration in Post-Cholestatic Rats Treated with the FXR Agonist Obeticholic Acid. Biomolecules, 2021, 11, 260.	4.0	4
7	Bile Salt and FGF19 Signaling in the Early Phase of Human Liver Regeneration. Hepatology Communications, 2021, 5, 1400-1411.	4.3	4
8	Chyme Reinfusion Restores the Regulatory Bile Saltâ€“FGF19 Axis in Patients With Intestinal Failure. Hepatology, 2021, 74, 2670-2683.	7.3	8
9	Hepatic Steatosis Contributes to the Development of Muscle Atrophy via Inter-Organ Crosstalk. Frontiers in Endocrinology, 2021, 12, 733625.	3.5	2
10	Differential Effects of One Meal per Day in the Evening on Metabolic Health and Physical Performance in Lean Individuals. Frontiers in Physiology, 2021, 12, 771944.	2.8	2
11	Bile acids drive the newbornâ€™s gut microbiota maturation. Nature Communications, 2020, 11, 3692.	12.8	100
12	Gut Microbes Take It to the Next Level? First Insights Into Farnesoid X Receptor Agonists of Microbial Origin. Hepatology, 2020, 72, 1483-1485.	7.3	3
13	Non-canonical Wnt signalling regulates scarring in biliary disease via the planar cell polarity receptors. Nature Communications, 2020, 11, 445.	12.8	31
14	Effect of wheat bran derived prebiotic supplementation on gastrointestinal transit, gut microbiota, and metabolic health: a randomized controlled trial in healthy adults with a slow gut transit. Gut Microbes, 2020, 12, 1704141.	9.8	46
15	The Role of Brown Adipose Tissue in the Development and Treatment of Nonalcoholic Steatohepatitis: An Exploratory Gene Expression Study in Mice. Hormone and Metabolic Research, 2020, 52, 869-876.	1.5	2
16	Differential effects of a 40-hour fast and bile acid supplementation on human GLP-1 and FGF19 responses. American Journal of Physiology - Endocrinology and Metabolism, 2019, 317, E494-E502.	3.5	9
17	Duodenal-jejunal lining increases postprandial unconjugated bile acid responses and disrupts the bile acid-FXR-FGF19 axis in humans. Metabolism: Clinical and Experimental, 2019, 93, 25-32.	3.4	13
18	Low circulating concentrations of citrulline and FGF19 predict chronic cholestasis and poor survival in adult patients with chronic intestinal failure: development of a Model for End-Stage Intestinal Failure (MESIF risk score). American Journal of Clinical Nutrition, 2019, 109, 1620-1629.	4.7	12

#	Article	IF	Citations
19	The cholic acid extension study in Zellweger spectrum disorders: Results and implications for therapy. Journal of Inherited Metabolic Disease, 2019, 42, 303-312.	3.6	18
20	Gallbladder Dyskinesia Is Associated With an Impaired Postprandial Fibroblast Growth Factor 19 Response in Critically Ill Patients. Hepatology, 2019, 70, 308-318.	7.3	7
21	Effect of Plasmapheresis on Cholestatic Pruritus and Autotaxin Activity During Pregnancy. Hepatology, 2019, 69, 2707-2710.	7.3	6
22	The role of macrophages in the development of biliary injury in a lipopolysaccharide-aggravated hepatic ischaemia-reperfusion model. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1284-1292.	3.8	15
23	Chronic elevation of plasma fibroblast growth factor 19 in longâ€term farnesoid X receptor agonist therapy, a happy marriage or cause for oncological concern?. Hepatology, 2018, 67, 782-784.	7.3	2
24	FXR agonist obeticholic acid induces liver growth but exacerbates biliary injury in rats with obstructive cholestasis. Scientific Reports, 2018, 8, 16529.	3.3	22
25	Cross-Species Molecular Imaging of Bile Salts and Lipids in Liver: Identification of Molecular Structural Markers in Health and Disease. Analytical Chemistry, 2018, 90, 11835-11846.	6.5	22
26	The cholic acid extension study in Zellweger spectrum disorders: results and implications for therapy. Journal of Inherited Metabolic Disease, 2018, , .	3.6	2
27	Ophthalmic acid as a read-out for hepatic glutathione metabolism in humans. Journal of Clinical and Translational Research, 2018, 3, 366-374.	0.3	0
28	FXR agonism protects against liver injury in a rat model of intestinal failure-associated liver disease. Journal of Clinical and Translational Research, 2018, 3, 318-327.	0.3	3
29	Effect of obeticholic acid on liver regeneration following portal vein embolization in an experimental model. British Journal of Surgery, 2017, 104, 590-599.	0.3	12
30	Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. Journal of Hepatology, 2017, 66, 1214-1222.	3.7	51
31	Cathepsin D regulates lipid metabolism in murine steatohepatitis. Scientific Reports, 2017, 7, 3494.	3.3	47
32	Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases. British Journal of Surgery, 2017, 104, 990-1002.	0.3	84
33	The ascending pathophysiology of cholestatic liver disease. Hepatology, 2017, 65, 722-738.	7.3	236
34	Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. Cell Metabolism, 2017, 26, 611-619.e6.	16.2	689
35	Interactions between bile salts, gut microbiota, and hepatic innate immunity. Immunological Reviews, 2017, 279, 23-35.	6.0	73
36	Validation of gene expression profiles from cholestatic hepatotoxicants in vitro against human in vivo cholestasis. Toxicology in Vitro, 2017, 44, 322-329.	2.4	10

#	Article	IF	Citations
37	Effects of acute dietary weight loss on postprandial plasma bile acid responses in obese insulin resistant subjects. Clinical Nutrition, 2017, 36, 1615-1620.	5.0	14
38	Parenteral nutrition dysregulates bile salt homeostasis in a rat model of parenteral nutrition-associated liver disease. Clinical Nutrition, 2017, 36, 1403-1410.	5.0	12
39	Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge. Hepatology International, 2017, 11, 132-140.	4.2	16
40	Lowâ€Ðose Lipopolysaccharide Causes Biliary Injury by Blood Biliary Barrier Impairment in a Rat Hepatic Ischemia/Reperfusion Model. Liver Transplantation, 2017, 23, 194-206.	2.4	4
41	Distinct fecal and oral microbiota composition in human type 1 diabetes, an observational study. PLoS ONE, 2017, 12, e0188475.	2.5	163
42	Serum Autotaxin Activity Correlates With Pruritus in Pediatric Cholestatic Disorders. Journal of Pediatric Gastroenterology and Nutrition, 2016, 62, 530-535.	1.8	27
43	Pandora's box opens for cholestatic liver disease. Hepatology, 2016, 63, 694-696.	7.3	2
44	Elevated interleukinâ€8 in bile of patients with primary sclerosing cholangitis. Liver International, 2016, 36, 1370-1377.	3.9	34
45	The portalâ€drained viscera release fibroblast growth factor 19 in humans. Physiological Reports, 2016, 4, e13037.	1.7	7
46	The role of bile salts in liver regeneration. Hepatology International, 2016, 10, 733-740.	4.2	28
47	Validation of the peak bilirubin criterion for outcome after partial hepatectomy. Hpb, 2016, 18, 806-812.	0.3	6
48	Cholic acid therapy in Zellweger spectrum disorders. Journal of Inherited Metabolic Disease, 2016, 39, 859-868.	3.6	37
49	Integrative â€œ-Omicsâ€•Analysis in Primary Human Hepatocytes Unravels Persistent Mechanisms of Cyclosporine A-Induced Cholestasis. Chemical Research in Toxicology, 2016, 29, 2164-2174.	3.3	14
50	The influence of chemotherapy-associated sinusoidal dilatation on short-term outcome after partial hepatectomy for colorectal liver metastases: A systematic review with meta-analysis. Surgical Oncology, 2016, 25, 298-307.	1.6	9
51	Liver resection for cancer: New developments in prediction, prevention and management of postresectional liver failure. Journal of Hepatology, 2016, 65, 1217-1231.	3.7	96
52	Cholangiocarcinoma, gone without the Wnt?. World Journal of Hepatology, 2016, 8, 1093.	2.0	7
53	Intestinal failure to produce FGF19: A culprit in intestinal failureâ€“associated liver disease?. Journal of Hepatology, 2015, 62, 1231-1233.	3.7	16
54	Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: Conjugated hypercholanemia without a clear clinical phenotype. Hepatology, 2015, 61, 260-267.	7.3	169

#	Article	IF	Citations
55	Pituitary TSH controls bile salt synthesis. Journal of Hepatology, 2015, 62, 1005-1007.	3.7	3
56	FXR, intestinal FiXeR of hepatocellular carcinoma?. Hepatology, 2015, 61, 21-23.	7.3	1
57	Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines. Oncotarget, 2015, 6, 12505-12519.	1.8	81
58	Impact of Global Fxr Deficiency on Experimental Acute Pancreatitis and Genetic Variation in the FXR Locus in Human Acute Pancreatitis. PLoS ONE, 2014, 9, e114393.	2.5	10
59	Yin Yang 1 and farnesoid X receptor: a balancing act in non-alcoholic fatty liver disease?. Gut, 2014, 63, 1-2.	12.1	22
60	How sweet it is to activate FXR. Hepatology, 2014, 59, 1665-1667.	7.3	3
61	Bile acid receptors as targets for drug development. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 55-67.	17.8	565
62	Calorie restriction and Rouxâ€enâ€Y gastric bypass have opposing effects on circulating <scp>FGF</scp>21 in morbidly obese subjects. Clinical Endocrinology, 2014, 81, 862-870.	2.4	57
63	Corrigendum to: â€œEffect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and healthâ€•[J Hepatol 2012;57:133â€“140]. Journal of Hepatology, 2014, 60, 684.	3.7	0
64	Prevention and reversal of hepatic steatosis with a high-protein diet in mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 685-695.	3.8	40
65	Accuracy of prediction scores and novel biomarkers for predicting nonalcoholic fatty liver disease in obese children. Obesity, 2013, 21, 583-590.	3.0	57
66	Prometheusâ€™ little helper, a novel role for fibroblast growth factor 15 in compensatory liver growth. Journal of Hepatology, 2013, 59, 1121-1123.	3.7	9
67	Fibroblast growth factor 21 is induced by endoplasmic reticulum stress. Biochimie, 2013, 95, 692-699.	2.6	141
68	Apolipoprotein A5 deficiency aggravates highâ€fat dietâ€induced obesity due to impaired central regulation of food intake. FASEB Journal, 2013, 27, 3354-3362.	0.5	11
69	The gut-liver axis. Current Opinion in Clinical Nutrition and Metabolic Care, 2013, 16, 576-581.	2.5	67
70	Mutations in the Isocitrate Dehydrogenase Genes IDH1 and IDH2 in Tumors. Advances in Anatomic Pathology, 2013, 20, 32-38.	4.3	73
71	Role of fibroblast growth factor 19 in the control of glucose homeostasis. Current Opinion in Clinical Nutrition and Metabolic Care, 2012, 15, 386-391.	2.5	40
72	Bile salts predict liver regeneration in rabbit model of portal vein embolization. Journal of Surgical Research, 2012, 178, 773-778.	1.6	16

#	Article	IF	Citations
73	Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health. Journal of Hepatology, 2012, 57, 133-140.	3.7	97
74	Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology, 2012, 56, 1391-1400.	7.3	228
75	Fibroblast Growth Factor 19, an Anticholestatic Drug Produced by Human Liver. Gastroenterology, 2012, 142, e29-e30.	1.3	3
76	Can Plasma Bile Salt, Triglycerides, and apoAâ€V Levels Predict Liver Regeneration?. World Journal of Surgery, 2012, 36, 2901-2908.	1.6	17
77	Pharmacological Activation of the Bile Acid Nuclear Farnesoid X Receptor Is Feasible in Patients with Quiescent Crohn's Colitis. PLoS ONE, 2012, 7, e49706.	2.5	22
78	The human gallbladder secretes fibroblast growth factor 19 into bile: Towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology, 2012, 55, 575-583.	7.3	111
79	Alterations of Hormonally Active Fibroblast Growth Factors after Roux-en-Y Gastric Bypass Surgery. Digestive Diseases, 2011, 29, 48-51.	1.9	118
80	The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. American Journal of Physiology - Renal Physiology, 2010, 298, G440-G445.	3.4	132
81	Plasma apolipoprotein AV levels in mice are positively associated with plasma triglyceride levels. Journal of Lipid Research, 2009, 50, 880-884.	4.2	13
82	High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology, 2009, 49, 1228-1235.	7.3	240
83	Efficient lowering of triglyceride levels in mice by human apoAV protein variants associated with hypertriglyceridemia. Biochemical and Biophysical Research Communications, 2009, 379, 542-546.	2.1	5
84	Estrogen induced hypertriglyceridemia in an apolipoprotein AV deficient patient. Journal of Internal Medicine, 2008, 263, 107-108.	6.0	14
85	Hypertriglyceridaemia and low plasma HDL in a patient with apolipoprotein Aâ€V deficiency due to a novel mutation in the APOA5 gene. Journal of Internal Medicine, 2008, 263, 450-458.	6.0	50
86	Determinants of plasma apolipoprotein Aâ€V and APOA5 gene transcripts in humans. Journal of Internal Medicine, 2008, 264, 452-462.	6.0	27
87	ApoE2-associated hypertriglyceridemia is ameliorated by increased levels of apoA-V but unaffected by apoC-III deficiency. Journal of Lipid Research, 2008, 49, 1048-1055.	4.2	5
88	Effects of Six APOA5 Variants, Identified in Patients With Severe Hypertriglyceridemia, on In Vitro Lipoprotein Lipase Activity and Receptor Binding. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1866-1871.	2.4	59
89	Changes in Hepatic ApoAV Expression are not Required for the Rapid Triglyceride Lowering Effect of Fish Oil Diet in Rats. Hormone and Metabolic Research, 2008, 40, 69-71.	1.5	4
90	Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism. Atherosclerosis, 2007, 193, 129-134.	0.8	71

#	Article	IF	Citations
91	A novel sequence variant in APOA5 gene found in patients with severe hypertriglyceridemia. Atherosclerosis, 2006, 188, 215-217.	0.8	47
92	Apolipoprotein AV does not contribute to hypertriglyceridaemia or triglyceride lowering by dietary fish oil and rosiglitazone in obese Zucker rats. Diabetologia, 2006, 49, 1324-1332.	6.3	19
93	Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study. Journal of Lipid Research, 2006, 47, 2064-2070.	4.2	84
94	Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia. Journal of Lipid Research, 2006, 47, 2333-2339.	4.2	52
95	Diosgenin-induced biliary cholesterol secretion in mice requires Abcg8. Hepatology, 2005, 41, 141-150.	7.3	38
96	Thyroid Hormone Regulates the Hypotriglyceridemic Gene APOA5. Journal of Biological Chemistry, 2005, 280, 27533-27543.	3.4	64
97	Hepatocyte Nuclear Factor-4Î± Regulates the Human Apolipoprotein AV Gene: Identification of a Novel Response Element and Involvement in the Control by Peroxisome Proliferator-Activated Receptor-Î³ Coactivator-1Î±, AMP-Activated Protein Kinase, and Mitogen-Activated Protein Kinase Pathway. Molecular Endocrinology, 2005, 19, 3107-3125.	3.7	32
98	ApoAV Reduces Plasma Triglycerides by Inhibiting Very Low Density Lipoprotein-Triglyceride (VLDL-TG) Production and Stimulating Lipoprotein Lipase-mediated VLDL-TG Hydrolysis. Journal of Biological Chemistry, 2004, 279, 27941-27947.	3.4	267
99	Cytoplasmic fatty acid-binding protein facilitates fatty acid utilization by skeletal muscle. Acta Physiologica Scandinavica, 2003, 178, 367-371.	2.2	137
100	Relation between hepatic expression of ATP-binding cassette transporters G5 and G8 and biliary cholesterol secretion in mice. Journal of Hepatology, 2003, 38, 710-716.	3.7	78
101	Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochemical and Biophysical Research Communications, 2002, 295, 1156-1159.	2.1	153
102	Evolution of the family of intracellular lipid binding proteins in vertebrates. Molecular and Cellular Biochemistry, 2002, 239, 69-77.	3.1	127
103	Evolution of the family of intracellular lipid binding proteins in vertebrates. Molecular and Cellular Biochemistry, 2002, 239, 69-77.	3.1	46
104	Impaired Long-Chain Fatty Acid Utilization by Cardiac Myocytes Isolated From Mice Lacking the Heart-Type Fatty Acid Binding Protein Gene. Circulation Research, 1999, 85, 329-337.	4.5	195
105	Cellular fatty acid transport in heart and skeletal muscle as facilitated by proteins. Lipids, 1999, 34, S169-S175.	1.7	107
106	Fatty acid-binding proteins in the heart. Molecular and Cellular Biochemistry, 1998, 180, 43-51.	3.1	77
107	Fatty acid-binding proteins in the heart. Molecular and Cellular Biochemistry, 1998, 180, 43-51.	3.1	26
108	Molecular cloning of fatty acid-transport protein cDNA from rat. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1997, 1354, 29-34.	2.4	37

#	Article	IF	Citations
109	One-step purification of rat heart-type fatty acid-binding protein expressed in Escherichia coli. Biomedical Applications, 1996, 679, 61-67.	1.7	16